Antibody therapy of cancer

@article{Scott2012AntibodyTO,
  title={Antibody therapy of cancer},
  author={Andrew Mark Scott and Jedd D. Wolchok and Lloyd J. Old},
  journal={Nature Reviews Cancer},
  year={2012},
  volume={12},
  pages={278-287}
}
The use of monoclonal antibodies (mAbs) for cancer therapy has achieved considerable success in recent years. Antibody–drug conjugates are powerful new treatment options for lymphomas and solid tumours, and immunomodulatory antibodies have also recently achieved remarkable clinical success. The development of therapeutic antibodies requires a deep understanding of cancer serology, protein-engineering techniques, mechanisms of action and resistance, and the interplay between the immune system… 
Monoclonal Antibodies for Cancer Immunotherapy
TLDR
This chapter concentrates on monoclonal antibodies as versatile platforms for cancer immunotherapy as well as the advantages of employing combinational therapies, and the limitations of antibody-based modalities.
Multi-Specific Antibodies for Cancer Immunotherapy
TLDR
This review will assess selected multi- specific antibodies in pre-clinical and clinical development that may be new treatment options for cancer patients in the very near future and assess the potential role of multi-specific antibodies in cancer treatment.
Antibody Therapy in Oncology
TLDR
The future for these and many other mAb-based drugs is very encouraging but will depend on the deep understanding of cancer biology, including its stroma and molecular regulation, on innovative approaches to target and antibody selection and on clever clinical trials that will guide appropriate development strategies, leading towards more specific and less toxic therapies for human cancer.
Current Development of Monoclonal Antibodies in Cancer Therapy.
TLDR
An overview of antibody structure and function relevant to cancer therapy is reviewed and an overview of pivotal clinical trials which have led to regulatory approval of monoclonal antibodies in cancer treatment is provided.
Antibodies as Cancer Immunotherapy
TLDR
This chapter will summarize the current FDA-approved antibodies to treat cancer, and highlight promising antibodies in development.
Monoclonal Antibodies in Cancer Therapy: Mechanisms, Successes and Limitations.
TLDR
The classification, efficacy and significantly reduced toxicity of CmAbs available for use in the United States of America are presented and future considerations are explored.
Antibody-Drug Conjugates : The Forefront of Targeted Chemotherapy for Cancer Treatment
TLDR
The design of chemical linkers to covalently bind these building blocks is making rapid progress but remains challenging, and recent successes show that the next generation of antibody-drug conjugates has come of age.
Antibody-Based Cancer Therapy: Successful Agents and Novel Approaches.
New approaches for cancer immunotherapy
TLDR
It is thought that particularly immune checkpoint inhibitors will play a crucial role in immunotherapeutic approaches, as they may enhance the efficacy of immunotherapy.
Building better monoclonal antibody-based therapeutics
TLDR
The various approaches to using mAb-based therapeutics to treat cancer and the strategies used to take advantage of the unique potential of each approach are discussed, and examples of current m Ab-based treatments are provided.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 65 REFERENCES
Antibodies in oncology.
Monoclonal antibodies: versatile platforms for cancer immunotherapy
TLDR
This work states that antibodies exhibit various immunomodulatory properties and, by directly activating or inhibiting molecules of the immune system, antibodies can promote the induction of antitumour immune responses and form the basis for new cancer treatment strategies.
Current constructs and targets in clinical development for antibody-based cancer therapy.
TLDR
This review tries to elucidate current trends in those antibody-based therapeutics that are currently in clinical development, and identifies two large trends: The movement towards increasingly molecularly defined recombinant constructs, and away from classical antibody effector functions in immune activation towards additional mechanisms of action.
Therapeutic antibodies for autoimmunity and inflammation
TLDR
How key insights obtained from the development of therapeutic antibodies complemented by newer antibody engineering technologies are delivering a second generation of therapeutic antibody with promise for greater clinical efficacy and safety is reviewed.
Nimotuzumab: a novel anti-EGFR monoclonal antibody that retains anti-EGFR activity while minimizing skin toxicity
TLDR
Nimotuzumab, a humanized murine mAb created in Cuba, has demonstrated antitumor activity similar to that of other anti-EGFR mAbs and shows promise as a single agent and as an adjunct to radiation in Phase I and II clinical trials.
Translating cancer research into targeted therapeutics
TLDR
The issues involved in cancer drug development are highlighted and ways in which this process can be improved and expedited are suggested.
VEGF-targeted therapy: mechanisms of anti-tumour activity
Several vascular endothelial growth factor (VEGF)-targeted agents, administered either as single agents or in combination with chemotherapy, have been shown to benefit patients with advanced-stage
Strategies and challenges for the next generation of therapeutic antibodies
TLDR
Strategies to select the best therapeutic antigen targets, to optimize the structure of IgG antibodies and to design related or new structures with additional functions are discussed.
Antibody-based vascular tumor targeting.
  • C. Schliemann, D. Neri
  • Biology
    Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer
  • 2010
TLDR
This chapter presents a selection of well-characterized markers of angiogenesis which have proven to be suitable targets for antibody-based vascular targeting approaches and describes different transcriptomic and proteomic methodologies for the discovery of novel vascular tumor markers.
Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape.
  • R. Ferris, E. Jaffee, S. Ferrone
  • Biology, Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2010
TLDR
The evidence that triggering of TA-specific cellular immunity by TA-targeted mAb, in conjunction with immune escape mechanisms used by tumor cells, may contribute to the differential clinical responses to mAb-based immunotherapy is discussed.
...
1
2
3
4
5
...